EGFR Antibody (ICR10) [PE]

Novus Biologicals, part of Bio-Techne | Catalog # NB100-64131

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NB100-64131-100Tests
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry

Label

PE (Excitation = 488 nm, Emission = 575 nm)

Antibody Source

Monoclonal Rat IgG2A Clone # ICR10

Concentration

LYOPH mg/ml

View all EGFR Antibodies »

Product Specifications

Immunogen

Extracellular domain of human EGF-receptor from head and neck carcinoma

Epitope

ICR10 binds to epitope B, and has an affinity of 6.7x10-9 M.

Localization

Cell Membrane and Secreted

Specificity

EGFR. It does not react with erb-B2.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Scientific Data Images for EGFR Antibody (ICR10) [PE]

EGFR Antibody (ICR10) [PE] Flow Cytometry: EGFR Antibody (ICR10) [PE] - [NB100-64131] -

Flow Cytometry: EGFR Antibody (ICR10) [PE] - [NB100-64131] -

Flow Cytometry: EGFR Antibody (ICR10) [PE] - [NB100-64131] - Figure A. PE conjugated Mouse anti Human CD49c and Alexa Fluor 647 conjugated Rat IgG2a isotype control Figure B . PE conjugated Rat anti Human CD49c and Alexa Fluor 647 conjugated Mouse anti Human EGFR All experiments performed on live single A431 cells, in the presence of 10% human serum. Data acquired on the ZE5 Cell Analyzer

Applications for EGFR Antibody (ICR10) [PE]

Application
Recommended Usage

Flow Cytometry

Neat
Application Notes
For Flow Cytometry, use 10 uL of the suggested working dilution to label 10^6 cells in 100 uL.

Formulation, Preparation, and Storage

Purification

Protein G purified

Reconstitution

Reconstitute with 1.0 mL deionized water.

Formulation

PBS

Preservative

0.09% Sodium Azide

Concentration

LYOPH mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: EGFR

Epidermal growth factor receptor (EGFR), also known as ErbB1 and HER1, is a type I glycoprotein that belongs the ErbB subfamily of receptor tyrosine kinases (RTKs), which includes ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4 (1,2). EGFR plays an important role in epithelial cell development and homeostasis and as a driver of tumorigenesis in cancer (1,2). The human EGFR is protein 1210 amino acids (aa) in length with a theoretical molecular weight (MW) of 134 kDa (1). The protein consists of a short signal peptide, an extracellular domain (ECD) divided into four subdomains (I-IV), a transmembrane region, an intracellular juxtamembrane segment, a tyrosine kinase domain, and C-terminal tail (1-3). Within the ECD, human EGFR has 88-90% aa sequence identity with mouse and rat EGFR. EGFR has four known specific ligands: EGF, amphiregulin, epigen, and transforming growth factor alpha (TGF-alpha). EGFR ligands betacellulin, epiregulin, and herapin binding (HB)-EGF have dual specificity with ErbB4 (1,3). Ligand binding to the extracellular domain of EFGR leads to receptor homodimerization, or heterodimerization with other ErbB family members, and EGFR activation. This results in subsequent phosphorylation and activation of intracellular signaling pathways, such as MAPK and PI3K/Akt (2,3). EGFR signaling is essential for many cellular processes including proliferation, differentiation, migration, and apoptosis (1,3,5).

In addition to its role in normal development, EGFR mutations or overexpression is observed in many tumors, including breast cancer, non-small cell lung carcinoma (NSCLC), colon cancer, and more (3-6). Small molecule tyrosine kinase inhibitors (TKIs), like gefitinib, erlotinib, and afatinib, have shown great efficacy in treating patients with EGFR activating mutations, especially for NSCLC (4-6). However, most patients eventually develop acquired resistance to TKIs and thus combination and alternative therapies are in development (4-6). A third-generation TKI, osimertinib, is approved for NSCLC patients with resistance to first-line EGFR TKI treatment (6). Additionally, combination therapies of EGFR TKIs with monoclonal antibody immunotherapies, like anti-PD-L1, are being further investigated in clinical trials (6).

References

1. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019; 139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014

2. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12(1):3-20. https://doi.org/10.1002/1878-0261.12155

3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018

4. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. https://doi.org/10.1186/s12943-018-0793-1

5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020; 61:167-179. https://doi.org/10.1016/j.semcancer.2019.09.015

6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1

Long Name

Epidermal Growth Factor Receptor

Alternate Names

EGF R, ErbB, ErbB1, HER-1

Gene Symbol

EGFR

UniProt

P00533

Additional EGFR Products

Product Documents for EGFR Antibody (ICR10) [PE]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for EGFR Antibody (ICR10) [PE]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.